88 related articles for article (PubMed ID: 326277)
1. [Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid].
Tohgi H; Ogawa M
No To Shinkei; 1977 Feb; 29(2):205-13. PubMed ID: 326277
[No Abstract] [Full Text] [Related]
2. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
Mars H
Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
[No Abstract] [Full Text] [Related]
3. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
Mars H
Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061
[No Abstract] [Full Text] [Related]
4. MK 486 and levodopa in treatment of Parkinsonism.
Lieberman AN; Derby BM; Feigenson J; Goodgold A; Nesbitte J; Resurreccion EC; Valdivia F
Dis Nerv Syst; 1973; 34(4):167-71. PubMed ID: 4711885
[No Abstract] [Full Text] [Related]
5. Levodopa and dopamine in cerebrospinal fluid.
Papavasiliou PS; Cotzias GC; Lawrence WH
Neurology; 1973 Jul; 23(7):756-9. PubMed ID: 4736493
[No Abstract] [Full Text] [Related]
6. A double-blind controlled study of MK-486 in Parkinson's disease.
Schwartz AM; Olanow CW; Spencer A
Trans Am Neurol Assoc; 1973; 98():301-3. PubMed ID: 4594189
[No Abstract] [Full Text] [Related]
7. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Mizuno Y; Yoshida M; Obayashi T; Ueki A
Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
[No Abstract] [Full Text] [Related]
8. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
[No Abstract] [Full Text] [Related]
9. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
Savery F
Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
[No Abstract] [Full Text] [Related]
10. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
Andrews CJ; Somerville B
Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
[No Abstract] [Full Text] [Related]
11. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
Confin Neurol; 1972; 34(2):143-8. PubMed ID: 4666057
[No Abstract] [Full Text] [Related]
12. An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
Mones RJ
J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):362-7. PubMed ID: 4714098
[TBL] [Abstract][Full Text] [Related]
13. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
Olanow CW; Gauger LL; Cedarbaum JM
Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185
[TBL] [Abstract][Full Text] [Related]
14. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
Fahn S
Neurology; 1974 May; 24(5):431-41. PubMed ID: 4857104
[No Abstract] [Full Text] [Related]
15. Evaluation of alpha methyl dopa and alpha methyl dopa hydrazine with L-dopa therapy.
Mones RJ
N Y State J Med; 1974 Jan; 74(1):47-51. PubMed ID: 4591989
[No Abstract] [Full Text] [Related]
16. [Results of the treatment of Parkinson's diseases with carbidopa and L-Dopa].
Cáceres AF
Rev Fac Cienc Med Cordoba; 1974; 32(2):161-74. PubMed ID: 4619691
[No Abstract] [Full Text] [Related]
17. [Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
Liu DK
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Apr; 13(4):223-6. PubMed ID: 6790255
[No Abstract] [Full Text] [Related]
18. Metabolism and clinical assessment of L-dopa in parkinsonism.
Ericsson AD; McCann D; Sharpless N; Reveno W
Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
[No Abstract] [Full Text] [Related]
19. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
Granerus AK; Jagenburg R; Rödjer S; Svanborg A
Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
[No Abstract] [Full Text] [Related]
20. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism.
Brashear A; Butler IJ; Hyland K; Farlow MR; Dobyns WB
Ann Neurol; 1998 Apr; 43(4):521-6. PubMed ID: 9546335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
